IPO registrations (S-1, F-1) · Registrants
TENAX THERAPEUTICS, INC.
- SEC CIK
- 34956 · filings on EDGAR ↗
- Former names
- OXYGEN BIOTHERAPEUTICS, INC. (2008–2014); SYNTHETIC BLOOD INTERNATIONAL INC (1996–2008)
- Registration
- Form S-1, first filed 2001-08-31, last 2024-02-02; 6 initial registrations, 10 amendments
- Outcome
- Final prospectus filed 2013-07-22; declared effective 2006-08-10; withdrawal requested 2008-12-01
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 101 GLEN LENNOX DRIVE, SUITE 300, Chapel Hill, NC 27517
- EIN
- 26-2593535
- Ticker
- TENX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- TENAX THERAPEUTICS, INC. on the corporate pages
On this site
- Business registration: OXYGEN BIOTHERAPEUTICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: TENAX THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: TENAX THERAPEUTICS, INC. EXACT (CIK (EXACT))
- SEC filer: OXYGEN BIOTHERAPEUTICS, INC. EXACT (CIK (EXACT))
- Person page: Chris A Rallis Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: J Melville Engle Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: John P Kelley Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 42
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2001-08-31 | S-1 | S-1 (registration) | SYNTHETIC BLOOD INTERNATIONAL INC | 0001013176-01-500174 ↗ |
| 2006-08-10 | EFFECT | EFFECT (declared effective) | SYNTHETIC BLOOD INTERNATIONAL INC | 9999999995-06-001146 ↗ |
| 2008-10-14 | S-1 | S-1 (registration) | OXYGEN BIOTHERAPEUTICS, INC. | 0001193125-08-209966 ↗ |
| 2008-12-01 | RW | RW (withdrawal request) | OXYGEN BIOTHERAPEUTICS, INC. | 0001020488-08-000137 ↗ |
| 2010-04-14 | EFFECT | EFFECT (declared effective) | OXYGEN BIOTHERAPEUTICS, INC. | 9999999995-10-001044 ↗ |
| 2013-03-22 | S-1 | S-1 (registration) | OXYGEN BIOTHERAPEUTICS, INC. | 0001354488-13-001406 ↗ |
| 2013-04-17 | EFFECT | EFFECT (declared effective) | OXYGEN BIOTHERAPEUTICS, INC. | 9999999995-13-001051 ↗ |
| 2013-04-22 | EFFECT | EFFECT (declared effective) | OXYGEN BIOTHERAPEUTICS, INC. | 9999999995-13-001102 ↗ |
| 2013-06-27 | S-1/A | S-1/A (amendment) | OXYGEN BIOTHERAPEUTICS, INC. | 0001354488-13-003663 ↗ |
| 2013-07-05 | S-1/A | S-1/A (amendment) | OXYGEN BIOTHERAPEUTICS, INC. | 0001354488-13-003816 ↗ |
| 2013-07-17 | S-1/A | S-1/A (amendment) | OXYGEN BIOTHERAPEUTICS, INC. | 0001354488-13-003937 ↗ |
| 2013-07-18 | S-1/A | S-1/A (amendment) | OXYGEN BIOTHERAPEUTICS, INC. | 0001354488-13-003953 ↗ |
| 2013-07-19 | EFFECT | EFFECT (declared effective) | OXYGEN BIOTHERAPEUTICS, INC. | 9999999995-13-002135 ↗ |
| 2013-07-22 | 424B1 | 424B1 (final prospectus) | OXYGEN BIOTHERAPEUTICS, INC. | 0001354488-13-004034 ↗ |
| 2013-10-10 | EFFECT | EFFECT (declared effective) | OXYGEN BIOTHERAPEUTICS, INC. | 9999999995-13-002943 ↗ |
| 2014-06-13 | EFFECT | EFFECT (declared effective) | OXYGEN BIOTHERAPEUTICS, INC. | 9999999995-14-001775 ↗ |
| 2014-09-08 | EFFECT | EFFECT (declared effective) | OXYGEN BIOTHERAPEUTICS, INC. | 9999999995-14-002691 ↗ |
| 2015-03-06 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-15-000546 ↗ |
| 2018-05-23 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-18-001328 ↗ |
| 2018-11-06 | S-1 | S-1 (registration) | TENAX THERAPEUTICS, INC. | 0001654954-18-012073 ↗ |
| 2018-11-20 | S-1/A | S-1/A (amendment) | TENAX THERAPEUTICS, INC. | 0001654954-18-013042 ↗ |
| 2018-12-03 | S-1/A | S-1/A (amendment) | TENAX THERAPEUTICS, INC. | 0001654954-18-013509 ↗ |
| 2018-12-06 | S-1/A | S-1/A (amendment) | TENAX THERAPEUTICS, INC. | 0001654954-18-013611 ↗ |
| 2018-12-07 | 424B4 | 424B4 (final prospectus) | TENAX THERAPEUTICS, INC. | 0001654954-18-013735 ↗ |
| 2018-12-07 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-18-003067 ↗ |
| 2020-09-30 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-20-002631 ↗ |
| 2021-09-01 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-21-003381 ↗ |
| 2022-06-03 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-22-001689 ↗ |
| 2023-01-23 | S-1 | S-1 (registration) | TENAX THERAPEUTICS, INC. | 0001654954-23-000693 ↗ |
| 2023-01-31 | S-1/A | S-1/A (amendment) | TENAX THERAPEUTICS, INC. | 0001654954-23-001107 ↗ |
| 2023-02-02 | S-1MEF | S-1MEF (added securities) | TENAX THERAPEUTICS, INC. | 0001654954-23-001233 ↗ |
| 2023-02-02 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-23-000261 ↗ |
| 2023-02-06 | 424B4 | 424B4 (final prospectus) | TENAX THERAPEUTICS, INC. | 0001654954-23-001338 ↗ |
| 2023-12-01 | S-1 | S-1 (registration) | TENAX THERAPEUTICS, INC. | 0001654954-23-015080 ↗ |
| 2024-02-01 | S-1/A | S-1/A (amendment) | TENAX THERAPEUTICS, INC. | 0001654954-24-001202 ↗ |
| 2024-02-02 | S-1/A | S-1/A (amendment) | TENAX THERAPEUTICS, INC. | 0001654954-24-001252 ↗ |
| 2024-02-07 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-24-000341 ↗ |
| 2024-02-09 | 424B4 | 424B4 (final prospectus) | TENAX THERAPEUTICS, INC. | 0001654954-24-001542 ↗ |
| 2024-04-12 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-24-000942 ↗ |
| 2024-04-12 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-24-000947 ↗ |
| 2024-09-12 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-24-002820 ↗ |
| 2025-04-23 | EFFECT | EFFECT (declared effective) | TENAX THERAPEUTICS, INC. | 9999999995-25-001213 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Eckert Rene | Director | 1 | 2010 | ||
| Jebsen Michael B | Officer | CFO; Chief Finanacial Officer; Chief Financial Officer; CHIEF FINANCIAL OFFICER; Interim CEO, President and CFO; President and CFO | 62 | 2010–2021 | |
| Kiral Richard M | Director; Director,Officer | President; President & COO | 4 | 2010–2011 | |
| Klein Gerald L | Director; Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 6 | 2010–2011 | |
| Spiess Bruce D | Director | 1 | 2010 | ||
| Stern Christian J | Director,Officer; Officer | CEO; Chairman and CEO; Chief Executive Officer | 7 | 2010–2011 | |
| ENGLE J MELVILLE | Director | 1 | 2010 | person page Fuzzy | |
| Harrington Kirk | Officer | SVP, Business Development | 1 | 2010 | |
| BLANCK RONALD R | Director | 14 | 2010–2020 | ||
| DiTonno Anthony A | Director; Director,Officer; Officer | CEO | 8 | 2012–2021 | |
| Chatfield William A. | Director | 2 | 2012 | ||
| RALLIS CHRIS A | Director | 5 | 2012–2020 | person page Fuzzy | |
| Kelley John P | Director,Officer; Officer | Chief Executive Officer | 4 | 2013–2017 | person page Fuzzy |
| Mitchum James P. | Director | 6 | 2016–2021 | ||
| PROEHL GERALD T | Director | 10 | 2016–2026 | ||
| ARMISTICE CAPITAL, LLC | Director; Director,TenPercentOwner; TenPercentOwner | 8 | 2020–2022 | ||
| Armistice Capital Master Fund Ltd. | Director; Director,TenPercentOwner; TenPercentOwner | 8 | 2020–2022 | ||
| Boyd Steven | Director; Director,TenPercentOwner; TenPercentOwner | 8 | 2020–2022 | ||
| Maher Illya Keith | Director | 1 | 2020 | ||
| Rich Stuart | Director,Officer; Director,Officer,TenPercentOwner; Officer | Chief Medical Officer | 12 | 2021–2026 | |
| Almenoff June Sherie | Director | 8 | 2021–2026 | ||
| Davidson Michael H. | Director | 7 | 2021–2026 | ||
| Doogan Declan | Director; Director,TenPercentOwner | 9 | 2021–2026 | ||
| Giordano Chrisopher Thomas | Director,Officer | CEO | 9 | 2021–2026 | |
| Lurier Eliot M | Officer | Interim CFO | 1 | 2021 | |
| Hunter Robyn | Director | 5 | 2022–2026 | ||
| HOFFMAN LAWRENCE R | Officer | Interim CFO | 1 | 2024 | |
| MCGAULEY THOMAS | Officer | Interim CFO | 3 | 2024–2026 | |
| Dellora Investments LP | Other; TenPercentOwner | 2 | 2025 | ||
| STAAB THOMAS R II | Officer | Chief Financial Officer | 3 | 2026 | |
| ADAR1 Capital Management, LLC | TenPercentOwner | 4 | 2026 | ||
| Schneeberger Daniel | TenPercentOwner | 4 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-08-23 | TENAX THERAPEUTICS, INC. | Pharmaceuticals | $174,999,993 | $99,681,169 | 24 | 1 |
| 2022-06-01 | TENAX THERAPEUTICS, INC. | Pharmaceuticals | $8,000,000 | $8,000,000 | 1 | 1 |
| 2021-07-20 | TENAX THERAPEUTICS, INC. | Pharmaceuticals | $9,999,998 | $9,999,998 | 1 | 1 |
| 2020-07-22 | TENAX THERAPEUTICS, INC. | Pharmaceuticals | $5,173,587 | $5,173,587 | 1 | 1 |
| 2020-03-27 | TENAX THERAPEUTICS, INC. | Pharmaceuticals | $317,167 | $317,167 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.